205676-86-4 Usage
General Description
ETHYL 2-[6-(METHYLAMINO)-2-PYRIDYL]ACETATE is a chemical compound with the molecular formula C11H15N2O2. It is known for its use in the pharmaceutical industry, particularly as an intermediate in the synthesis of various drugs. ETHYL 2-[6-(METHYLAMINO)-2-PYRIDYL]ACETATE is a derivative of pyridine and acetate, and it is commonly used in the production of medications that target the central nervous system and the cardiovascular system. It has also been investigated for its potential use in the treatment of various diseases such as certain types of cancer. Overall, ETHYL 2-[6-(METHYLAMINO)-2-PYRIDYL]ACETATE is a valuable chemical in the pharmaceutical industry with potential therapeutic applications.
Check Digit Verification of cas no
The CAS Registry Mumber 205676-86-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,5,6,7 and 6 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 205676-86:
(8*2)+(7*0)+(6*5)+(5*6)+(4*7)+(3*6)+(2*8)+(1*6)=144
144 % 10 = 4
So 205676-86-4 is a valid CAS Registry Number.
205676-86-4Relevant articles and documents
Design, synthesis, and biological evaluation of novel potent and selective αvβ3/αvβ5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core
Marugán, Juan José,Manthey, Carl,Anaclerio, Beth,Lafrance, Lou,Lu, Tianbao,Markotan, Tom,Leonard, Kristi A.,Crysler, Carl,Eisennagel, Stephen,Dasgupta, Malini,Tomczuk, Bruce
, p. 926 - 934 (2007/10/03)
A novel series of potent and selective αvβ 3/αvβ5 dual inhibitors was designed, synthesized, and evaluated against several integrins. These compounds were synthesized through a Mitsunobu reaction between the gua
Vitronectin receptor antagonists
-
, (2008/06/13)
Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.
Vitronectin receptor antagonists
-
, (2008/06/13)
Compounds of the formula (I) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis: or a pharmaceutically acceptable salt thereof.
